BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 31837200)

  • 1. Exploring the potential association among sleep disturbances, cognitive impairments, and immune activation in 22q11.2 deletion syndrome.
    Yirmiya ET; Mekori-Domachevsky E; Weinberger R; Taler M; Carmel M; Gothelf D
    Am J Med Genet A; 2020 Mar; 182(3):461-468. PubMed ID: 31837200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated Proinflammatory Markers in 22q11.2 Deletion Syndrome Are Associated With Psychosis and Cognitive Deficits.
    Mekori-Domachevsky E; Taler M; Shoenfeld Y; Gurevich M; Sonis P; Weisman O; Weizman A; Gothelf D
    J Clin Psychiatry; 2017; 78(9):e1219-e1225. PubMed ID: 29141125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Education and employment trajectories from childhood to adulthood in individuals with 22q11.2 deletion syndrome.
    Mosheva M; Pouillard V; Fishman Y; Dubourg L; Sofrin-Frumer D; Serur Y; Weizman A; Eliez S; Gothelf D; Schneider M
    Eur Child Adolesc Psychiatry; 2019 Jan; 28(1):31-42. PubMed ID: 29934817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subthreshold social cognitive deficits may be a key to distinguish 22q11.2DS from schizophrenia.
    Peyroux E; Rigard C; Saucourt G; Poisson A; Plasse J; Franck N; Demily C
    Early Interv Psychiatry; 2019 Apr; 13(2):304-307. PubMed ID: 29575660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Neurocognitive and psychiatric management of the 22q11.2 deletion syndrome].
    Demily C; Rossi M; Schneider M; Edery P; Leleu A; d'Amato T; Franck N; Eliez S
    Encephale; 2015 Jun; 41(3):266-73. PubMed ID: 25523123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-pharmacological treatment of psychiatric disorders in individuals with 22q11.2 deletion syndrome; a systematic review.
    Buijs PCM; Bassett AS; Boot E
    Am J Med Genet A; 2018 Aug; 176(8):1742-1747. PubMed ID: 29363845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sleep in 22q11.2 Deletion Syndrome: Current Findings, Challenges, and Future Directions.
    O'Hora KP; Schleifer CH; Bearden CE
    Curr Psychiatry Rep; 2023 Oct; 25(10):479-491. PubMed ID: 37721640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developmental trajectories of brain structure in adolescents with 22q11.2 deletion syndrome: a longitudinal study.
    Gothelf D; Penniman L; Gu E; Eliez S; Reiss AL
    Schizophr Res; 2007 Nov; 96(1-3):72-81. PubMed ID: 17804201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sleep problems and associations with psychopathology and cognition in young people with 22q11.2 deletion syndrome (22q11.2DS).
    Moulding HA; Bartsch U; Hall J; Jones MW; Linden DE; Owen MJ; van den Bree MBM
    Psychol Med; 2020 May; 50(7):1191-1202. PubMed ID: 31144615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High prevalence of fatigue in adults with a 22q11.2 deletion syndrome.
    Vergaelen E; Claes S; Kempke S; Swillen A
    Am J Med Genet A; 2017 Apr; 173(4):858-867. PubMed ID: 28190295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative study of the neuropsychiatric and neurocognitive phenotype in two microdeletion syndromes: velocardiofacial (22q11.2 deletion) and Williams (7q11.23 deletion) syndromes.
    Zarchi O; Diamond A; Weinberger R; Abbott D; Carmel M; Frisch A; Michaelovsky E; Gruber R; Green T; Weizman A; Gothelf D
    Eur Psychiatry; 2014 May; 29(4):203-10. PubMed ID: 24054518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predominant negative symptoms in 22q11.2 deletion syndrome and their associations with cognitive functioning and functional outcome.
    Schneider M; Van der Linden M; Menghetti S; Glaser B; Debbané M; Eliez S
    J Psychiatr Res; 2014 Jan; 48(1):86-93. PubMed ID: 24189154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between intelligence quotient measures and computerized neurocognitive performance in 22q11.2 deletion syndrome.
    Gur RC; Moore TM; Weinberger R; Mekori-Domachevsky E; Gross R; Emanuel BS; Zackai EH; Moss E; Gallagher RS; McGinn DE; Crowley TB; McDonald-McGinn D; Gothelf D; Gur RE
    Brain Behav; 2021 Aug; 11(8):e2221. PubMed ID: 34213087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurocognitive Functioning in Patients with 22q11.2 Deletion Syndrome: A Meta-Analytic Review.
    Moberg PJ; Richman MJ; Roalf DR; Morse CL; Graefe AC; Brennan L; Vickers K; Tsering W; Kamath V; Turetsky BI; Gur RC; Gur RE
    Behav Genet; 2018 Jul; 48(4):259-270. PubMed ID: 29922984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deep psychophysiological phenotyping of adolescents and adults with 22q11.2 deletion syndrome: a multilevel approach to defining core disease processes.
    Parker DA; Cubells JF; Imes SL; Ruban GA; Henshey BT; Massa NM; Walker EF; Duncan EJ; Ousley OY
    BMC Psychiatry; 2023 Jun; 23(1):425. PubMed ID: 37312091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An examination of the relationship of anxiety and intelligence to adaptive functioning in children with chromosome 22q11.2 deletion syndrome.
    Angkustsiri K; Leckliter I; Tartaglia N; Beaton EA; Enriquez J; Simon TJ
    J Dev Behav Pediatr; 2012; 33(9):713-20. PubMed ID: 23117596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological effects of COMT haplotypes and psychosis risk in 22q11.2 deletion syndrome.
    Gothelf D; Law AJ; Frisch A; Chen J; Zarchi O; Michaelovsky E; Ren-Patterson R; Lipska BK; Carmel M; Kolachana B; Weizman A; Weinberger DR
    Biol Psychiatry; 2014 Mar; 75(5):406-13. PubMed ID: 23992923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Further evidence for high rates of schizophrenia in 22q11.2 deletion syndrome.
    Monks S; Niarchou M; Davies AR; Walters JT; Williams N; Owen MJ; van den Bree MB; Murphy KC
    Schizophr Res; 2014 Mar; 153(1-3):231-6. PubMed ID: 24534796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Candidate genes and the behavioral phenotype in 22q11.2 deletion syndrome.
    Prasad SE; Howley S; Murphy KC
    Dev Disabil Res Rev; 2008; 14(1):26-34. PubMed ID: 18636634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Negative subthreshold psychotic symptoms distinguish 22q11.2 deletion syndrome from other neurodevelopmental disorders: A two-site study.
    Mekori-Domachevsky E; Guri Y; Yi J; Weisman O; Calkins ME; Tang SX; Gross R; McDonald-McGinn DM; Emanuel BS; Zackai EH; Zalsman G; Weizman A; Gur RC; Gur RE; Gothelf D
    Schizophr Res; 2017 Oct; 188():42-49. PubMed ID: 28041919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.